MASHINIi

Genelux Corporation.

GNLX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing a portfolio of next-generation oncolytic viruses for the treatment of patients with advanced, treatment-refractory cancers. Their lead product candidate, Olvi-Vec, is an oncolytic vaccinia virus that has dem...Show More

Ethical Profile

Mixed.

Genelux Corporation (GNLX.US) receives a mixed ethical rating. The company is actively developing Olvi-Vec, an oncolytic virus immunotherapy for difficult-to-treat cancers. Phase 1b/2 data for small cell lung cancer reportedly showed a 71% disease control rate, with some patients experiencing tumor reductions up to 79%. Olvi-Vec has been administered to over 150 patients in clinical studies with a manageable safety profile, primarily mild to moderate adverse events. While the experimental drug is free during trials, its ultimate price accessibility remains unknown as the company is still in the clinical stage.

Value Scores

Better Health for All20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

20

Genelux Corporation's core business is developing oncolytic virus therapies for advanced, treatment-refractory cancers, with 100% of its portfolio dedicated to this, demonstrating a revolutionary health benefit. The company currently has no revenue from products with negative health outcomes. Olvi-Vec has been administered to over 150 patients across seven trials, showing a manageable safety profile with most treatment-related adverse effects being mild to moderate, and no maximum tolerated dose reached.

1
For trial participants, the experimental drug and research-related procedures are free, though standard care medications are billed separately.
2
Clinical trials are open to women 18+ with platinum-resistant/refractory ovarian cancer, regardless of BRCA, HR, or MMR status, and without limitations on prior lines of therapy, indicating a broad reach to a vulnerable population.
3
Trial details, including potential side effects, are provided, and trials are conducted according to ethical standards with NCT identifiers and ethics approvals from AdventHealth IRB and GOG-3076.
4

Fair Money & Economic Opportunity

0

No evidence available to assess Genelux Corporation on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage was provided in the article.

1

Fair Trade & Ethical Sourcing

0

No evidence available to assess Genelux Corporation on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess Genelux Corporation on Honest & Fair Business.

Kind to Animals

0

No evidence available to assess Genelux Corporation on Kind to Animals.

No War, No Weapons

0

No relevant evidence was found in the provided articles to assess Genelux Corporation against the 'No War, No Weapons' ethical value. Article

1
pertains to Gentex Corporation, a different entity, and Articles
2
and
3
describe an XBRL viewer without providing any specific data for Genelux Corporation.
4

Planet-Friendly Business

0

The provided articles offer general ESG risk ratings and industry rankings for Genelux Corporation but do not contain specific, quantitative data points for any of the environmental KPIs in the rubric.

1
There is no information on carbon emissions, renewable energy use, water consumption, waste diversion, green building certifications, or any climate-related targets or initiatives.
2

Respect for Cultures & Communities

0

No information relevant to the 'Respect for Cultures & Communities' value was found in the provided articles.

1
The articles focus on investor relations, company updates, and clinical trial results, without addressing any of the specified KPIs related to cultural engagement, community partnerships, or social impact.

Safe & Smart Tech

0

No evidence available to assess Genelux Corporation on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No evidence available to assess Genelux Corporation on Zero Waste & Sustainable Products.

Own Genelux Corporation?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.